{ "meta": { "data_length": 1, "message": "Statement id stmt:hse:00901:a:2 retrieved successfully", "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Ahse%3A00901%3Aa%3A2", "status": "success", "status_code": 200, "timestamp_elapsed": 0.001995, "timestamp_received": "2026-10-16T23:58:46.528062+00:00Z", "timestamp_returned": "2026-10-16T23:58:46.530057+00:00Z", "trace_id": "8bbace4e-3201-408f-97a3-54cd6bfebb8d" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:hse:00901:a:2", "type": "Statement", "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ivosidenib as a treatment option for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated with at least one prior line of systemic therapy.", "contributions": [ { "id": "ctrb:hse:2025-10-01:0", "type": "Contribution", "description": "Indication approved for reimbursement.", "date": "2025-10-01", "contributor": { "id": "agent:org:hse", "type": "Agent", "agentType": "organization", "name": "Health Service Executive", "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland." } }, { "id": "ctrb:vanallenlab:2024-01-16:0", "type": "Contribution", "description": "Adding HSE approvals for reimbursement to database", "date": "2024-01-16", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } } ], "reportedIn": [ { "id": "doc:hse:00901", "type": "Document", "documentType": "Regulatory approval", "name": "Ivosidenib Therapy. NCCP National SACT Regimen. HSE.", "title": null, "aliases": [], "description": "Ivosidenib Therapy, 2025, version number 1a, viewed 02/08/2026, https://healthservice.hse.ie/documents/6654/901_v1a_Ivosidenib.pdf", "urls": [ "https://healthservice.hse.ie/documents/6654/901_v1a_Ivosidenib.pdf" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:hse", "type": "Agent", "agentType": "organization", "name": "Health Service Executive", "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland." }, "description": "The organization that published this document." }, { "name": "company", "value": "", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": null, "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": null, "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-12-02", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:192", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:ncit:C4436", "conceptType": "Disease", "name": "Cholangiocarcinoma", "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:oncotree:CHOL", "code": "CHOL", "name": "Cholangiocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2025_10_03", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Cholangiocarcinoma+%28CHOL%29" ] } } ], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:ncit:C4436", "code": "C4436", "name": "Cholangiocarcinoma", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C4436" ] } }, "objectTherapeutic": { "id": "tx:ncit:C114383", "conceptType": "Therapy", "name": "Ivosidenib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:2049873", "code": "2049873", "name": "ivosidenib", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2049873" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1560123", "code": "1560123", "name": "ivosidenib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1560123" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "IDH1 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C114383", "code": "C114383", "name": "Ivosidenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383" ] } }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:76", "present": true, "subject": { "id": "bmkr:76", "type": "CategoricalVariant", "name": "IDH1 p.R132H", "constraints": [ { "type": "DefiningAlleleConstraint", "allele": { "id": "ga4gh:VA.2VAvTmPON2L7JffxjE68jAmmmwxyzDpB", "type": "Allele", "name": "NP_005887.2:p.Arg132His", "aliases": [ "NP_005887.2:p.R132H", "IDH1 p.R132H" ], "description": "VRS variation of NP_005887.2:p.Arg132His", "digest": "2VAvTmPON2L7JffxjE68jAmmmwxyzDpB", "expressions": [ { "syntax": "hgvs.p", "value": "NP_005887.2:p.Arg132His", "extensions": [ { "name": "hgvs.p_short", "value": "p.R132H" } ] } ], "location": { "id": "ga4gh:SL.c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Amino acid position 132 of the Refseq protein NP_005887.2, which is the protein product of the MANE Select coding transcript for IDH1 (refseq:NM_005896.4).", "digest": "c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "sequenceReference": { "id": "ga4gh:SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ", "type": "SequenceReference", "name": "NP_005887.2", "aliases": [ "ensembl:ENSP00000260985.2", "ga4gh:SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ", "refseq:NP_005887.2" ], "description": "The protein product of the MANE Select coding transcript for IDH1 (refseq:NM_005896.4), corresponding to the Refseq protein accession NP_005887.2.", "moleculeType": "protein", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ", "residueAlphabet": "aa" }, "start": 131, "end": 132, "sequence": "R" }, "state": { "type": "LiteralSequenceExpression", "sequence": "H" } }, "relations": [] }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:5382", "conceptType": "Gene", "name": "IDH1", "primaryCoding": { "id": "coding:hgnc:5382", "code": "HGNC:5382", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000138413", "code": "ENSG00000138413", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000138413" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:3417", "code": "3417", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/3417" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_005896.4", "code": "NM_005896.4", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Somatic variant" }, { "name": "chromosome", "value": "2" }, { "name": "start_position", "value": 209113112 }, { "name": "end_position", "value": 209113112 }, { "name": "reference_allele", "value": "C" }, { "name": "alternate_allele", "value": "T" }, { "name": "cdna_change", "value": "c.395G>A" }, { "name": "protein_change", "value": "p.R132H" }, { "name": "variant_annotation", "value": "Missense" }, { "name": "exon", "value": 4 }, { "name": "rsid", "value": "rs121913500" }, { "name": "hgvsg", "value": "2:g.209113112C>T" }, { "name": "hgvsc", "value": "ENST00000345146.2:c.395G>A" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:hse:00901:a", "type": "Indication", "description": "As monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated with at least one prior line of systemic therapy.", "contributions": [ { "id": "ctrb:hse:2025-10-01:0", "type": "Contribution", "description": "Indication approved for reimbursement.", "date": "2025-10-01", "contributor": { "id": "agent:org:hse", "type": "Agent", "agentType": "organization", "name": "Health Service Executive", "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland." } }, { "id": "ctrb:vanallenlab:2024-01-16:0", "type": "Contribution", "description": "Adding HSE approvals for reimbursement to database", "date": "2024-01-16", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } } ], "reportedIn": [ { "id": "doc:hse:00901", "type": "Document", "documentType": "Regulatory approval", "name": "Ivosidenib Therapy. NCCP National SACT Regimen. HSE.", "title": null, "aliases": [], "description": "Ivosidenib Therapy, 2025, version number 1a, viewed 02/08/2026, https://healthservice.hse.ie/documents/6654/901_v1a_Ivosidenib.pdf", "urls": [ "https://healthservice.hse.ie/documents/6654/901_v1a_Ivosidenib.pdf" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:hse", "type": "Agent", "agentType": "organization", "name": "Health Service Executive", "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland." }, "description": "The organization that published this document." }, { "name": "company", "value": "", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": null, "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": null, "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-12-02", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." }, { "name": "reimbursement_scheme", "value": "CDS", "description": "Current scheme used to reimburse indication." }, { "name": "reimbursement_comment", "value": null, "description": "More details about the current reimbursement scheme(s)." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }